Members asked about the potential to include consideration of synthesized delta-9-THC in open rulemaking and had a lengthy discussion on the tone of official statements on the matter.
Board members entertained a possible public relations effort around delta-8-THC before they learned what other states had done or were attempting to do to control use of the compound.
Amidst long solstice days after a week of high temperatures, important decisions about the future of the Washington state cannabis industry were under way - and more heat was expected.
A board member called a special caucus to air confusion about investigating a licensed processor turning CBD into delta-9-THC, kicking off a debate about the law and potential board action.
After a presentation on prospective Department of Commerce grant and mentorship programs for equity applicants, work group members and the public delved into potential details.
A panel of experts discussed the chemistry of the cannabis plant and its pharmacology with a focus on the conversion of CBD into other cannabinoids for commercial products.
During a quiet summer week, the Social Equity Task Force Disproportionately Impacted Communities Work Group would continue clarifying the next retail application window.
A “wave of interest” around the WSLCB-approved Joints for Jabs vaccination program provoked both media inquiry and criticism while the board and staff remained confident in the program.
During a hearing on tier 1 canopy and public comment, licensees and citizens spoke to perceived limitations of the Joints for Jabs program, hemp biomass, and market structure.
Board members welcomed a new deputy director and were brought up to speed on the Joints for Jabs program, external meetings involving agency staff, and ongoing rulemaking projects.